Substantia Nigra - Drug effects
Research News and Information

Sunday, November 22, 2009

Chronic nicotine selectively enhances alpha4beta2* nicotinic acetylcholine receptors in the nigrostriatal dopamine pathway.

5 Oct 2009 These electrophysiological experiments, in slices and intact animals, study the effects of in vivo chronic exposure to nicotine on functional alpha4beta2* nAChRs in the nigrostriatal dopaminergic (DA) pathway. Recordings were made in wild-type and ... Read more...

Acute and chronic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administrations elicit similar microglial activation in the substantia nigra of monkeys.

30 Aug 2009 Increasing evidence suggests a pivotal role for neuroinflammation in the pathogenesis of Parkinson disease, but whether activated microglia participate in disease progression remains unclear. To clarify this issue, we determined the numbers of ... Read more...

Effects of early vs. late initiation of levodopa treatment in hemiparkinsonian rats.

25 Aug 2009 We investigated the effect of early vs. late initiation of levodopa treatment on dyskinetic movements, rotational behavior and molecular markers in hemiparkinsonian rats. Male Sprague-Dawley rats received a unilateral 6-hydroxydopamine (6-OHDA) ... Read more...

Latest indexed articles for 'Substantia Nigra - Drug effects'

These are the very latest articles for this heading:

• Chronic nicotine selectively enhances alpha4beta2* nicotinic acetylcholine receptors in the nigrostriatal dopamine pathway. 5 Oct 2009
• Acute and chronic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administrations elicit similar microglial activation in the substantia nigra of monkeys. 30 Aug 2009
• Effects of early vs. late initiation of levodopa treatment in hemiparkinsonian rats. 25 Aug 2009
• Neocortical movement representations are reduced and reorganized following bilateral intrastriatal 6-hydroxydopamine infusion and dopamine type-2 receptor antagonism. 20 Aug 2009
• Parkinsonism in hiv-infected patients on highly active antiretroviral therapy. 2 Aug 2009
• Medical treatment of Parkinson disease. 30 Jul 2009
• Mesencephalic astrocyte-derived neurotrophic factor is neurorestorative in rat model of Parkinson's disease. 27 Jul 2009
• Subchronic infusion of the product of inflammation prostaglandin J2 models sporadic Parkinson's disease in mice. 23 Jul 2009
• Effects of glutamate and alpha2-noradrenergic receptor antagonists on the development of neurotoxicity produced by chronic rotenone in rats. 15 Jul 2009
• Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson's disease. 29 Jun 2009
• Beneficial effects of antioxidant-enriched diet for tyrosine hydroxylase-positive neurons in ventral mesencephalic tissue in oculo grafts. 29 Jun 2009
• Impact of serotonin 2C receptor null mutation on physiology and behavior associated with nigrostriatal dopamine pathway function. 22 Jun 2009
• Effects of dopamine depletion on network entropy in the external globus pallidus. 15 Jun 2009
• Evidence for a dopaminergic innervation of the pedunculopontine nucleus in monkeys, and its drastic reduction after MPTP intoxication. 10 Jun 2009
• Impaired glutamate homeostasis and programmed cell death in a chronic MPTP mouse model of Parkinson's disease. 9 Jun 2009
• Amphetamine-evoked rotation requires newly synthesized dopamine at 14 days but not 1 day after intranigral 6-OHDA and is consistently dissociated from sensorimotor behavior. 6 Jun 2009
• Behavioral and quantitative mitochondrial proteome analyses of the effects of simvastatin: implications for models of neural degeneration. 4 Jun 2009
• Effects of scoparone on dopamine biosynthesis and L-DOPA-induced cytotoxicity in PC12 cells. 30 May 2009
• Nicotine modulates GABAergic transmission to dopaminergic neurons in substantia nigra pars compacta. 30 May 2009
• Long term exposure to the chemokine CCL2 activates the nigrostriatal dopamine system: a novel mechanism for the control of dopamine release. 25 May 2009

See a longer list of these articles.

Technical information about 'Substantia Nigra'

Definition: The black substance in the ventral midbrain or the nucleus of cells containing the black substance. These cells produce DOPAMINE, an important neurotransmitter in regulation of the sensorimotor system and mood. The dark colored MELANIN is a by-product of dopamine synthesis.

Descriptor UI: D013378

Alternative terms: Substantia Nigra; Nigra, Substantia; Nigras, Substantia; Substantia Nigras;

Allowable Qualifiers: abnormalities; anatomy & histology; blood supply; cytology; drug effects; embryology; enzymology; growth & development; immunology; injuries; metabolism; microbiology; parasitology; pathology; physiology; physiopathology; radiation effects; radiography; radionuclide imaging; secretion; surgery; transplantation; ultrastructure; ultrasonography; chemistry; virology;

Tree Number: A08.186.211.132.659.822.731; A08.186.211.653.822.731;